Youngson Kim
About Youngson Kim
Youngson Kim serves as the Associate Director of QCQA at Mirum Pharmaceuticals, Inc., bringing over 15 years of experience in ensuring compliance with cGMP standards in the pharmaceutical industry.
Work at Mirum Pharmaceuticals
Youngson Kim serves as the Associate Director of QCQA at Mirum Pharmaceuticals, Inc. since 2021. In this role, he is responsible for overseeing quality control and quality assurance processes, ensuring compliance with current Good Manufacturing Practices (cGMP) standards. His extensive experience in the pharmaceutical industry supports his ability to manage quality systems effectively within the organization.
Previous Experience in Quality Assurance
Before joining Mirum Pharmaceuticals, Youngson Kim held several key positions in quality assurance. He worked as a Senior Quality Assurance Manager at Versartis, Inc. for one year and served as Associate Director of Quality Assurance at Corcept Therapeutics for three years. His background includes roles at Relypsa, Lantheus Medical Imaging, and AstraZeneca, where he contributed to various quality assurance initiatives.
Education and Expertise
Youngson Kim earned a Bachelor of Science degree in Chemistry from the University of Massachusetts Dartmouth. His educational background provides a strong foundation for his analytical skills and expertise in quality assurance within the pharmaceutical sector. He possesses a strong analytical mindset, focusing on troubleshooting and resolving quality issues efficiently.
Career Background in Pharmaceuticals
With over 15 years of experience in supporting commercial drug product manufacturing sites, Youngson Kim has developed a robust career in the pharmaceutical industry. His roles have included positions at Relypsa, where he worked as a Manager/Sr. Quality Specialist and Staff Scientist in the Analytical Development Group, and AstraZeneca, where he held various scientific and quality assurance roles.
Contributions to Drug Development
Youngson Kim played a significant role in the development and commercialization of Pulmicort Respules and Veltassa. His contributions were instrumental in supporting their successful market launch, showcasing his ability to collaborate effectively with multi-site and multi-functional teams to achieve project goals.